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Two-thirds of all breast cancers are detected after the menopause,
when ovarian oestrogen production has virtually ceased. Despite
this, oestrogen levels within breast tumours remain high and it has
been demonstrated that these tumours possess enzyme systems
required to produce bioactive oestrogens in situ from circulating
precursors androstendione or oestrone sulphate (Pasqualini et al,
1996a; Peltoketo et al, 1996). In post-menopausal women, these
systems are particularly active. The two main routes for oestrogen
synthesis within breast tumours from post-menopausal women
involve activity of three principal enzyme groups: aromatase,
oestrone sulphatase (STS) and 17b-hydroxysteroid dehydrogenase
(17-HSD).
The 17-HSD enzyme complex controls the final step in the
formation of all androgens and oestrogens, and thus plays a key
role in regulating local hormone concentrations (reviewed in
Labrie et al, 1997). To date, six distinct isoforms of 17-HSD, desig-
nated I–VI, have been identified and cloned. The type I enzyme
uses NADPH as a cofactor and catalyses the interconversion of
the weak oestrogen, oestrone (E1) to the biologically more
potent 17b-oestradiol (E2; Peltoketo et al, 1996; Penning, 1996).
Using NAD+ as cofactor, 17-HSD II catalyses the oxidation of
testosterone and E2 to form androstendione and E1 respectively 
(Luu-The et al, 1995; Penning, 1996). This isoform also possesses
20a-hydroxylase activity by converting 20a-dihydroprogesterone
to progesterone (Casey et al, 1994). The androgenic 17-HSD III
prefers NADPH as cofactor and reduces androstendione to testos-
terone (as can 17-HSD type I, but to a much lesser extent; Luu-
The et al, 1995), and also reduces dehydroepiandrosterone to
5-androstenediol (Andersson, 1995; Luu-The et al, 1995). This
isoform is found principally in the testis. Type IV 17-HSD is
similar to the type II isoform in that it is NAD+-dependent and is
principally involved in the oxidation and therefore inactivation of
oestrogens and androgens (Adamski et al, 1992). 17-HSD type V
belongs to the aldoketoreductase family (Jornvall et al, 1995)
while the sixth isoform is a member of the short-chain alcohol
reductase family (Deyashiki et al, 1995). A seventh murine
isoform of 17-HSD, present in corpus luteum and which possesses
reductive activity has recently been described (Nokelainen et al,
1998).
In addition to 17-HSD, aromatase and STS also contribute to the
high local concentrations of E2 observed within breast tumours of
post-menopausal women (Reed and Purohit, 1997). Aromatase, a
product of the CYP19 gene, catalyses the aromatization of C19
steroids (androstendione, testosterone and 16a-hydroxyandrosten-
dione) to E1 and E2 (Guengerich, 1992; Simpson et al, 1994). It
belongs to the cytochrome P450 family of enzymes. STS is
responsible for the hydrolysis of oestrone sulphate to oestrone, and
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this pathway is of particular importance in breast tumours as it
results in up to ten times more free oestrone than the aromatase
pathway (Santer et al, 1984).
As concentrations of oestrogens within breast tumours are
significantly higher than plasma levels (Pasqualini et al, 1996) this
suggests that in situ production of these hormones is critical.
Because of their involvement in the in situ production of E2, the
steroid-converting enzymes described above are clearly important
in breast cancer progression, but no study to date has addressed the
simultaneous expression of all six of these enzymes in breast
tumours. Therefore to provide a more precise overview of the
expression of gene transcripts for these enzymes in breast cancer,
we have determined expression of isoforms I–IV of 17-HSD,
aromatase and STS in a series of human breast tumours using
reverse transcription polymerase chain reaction (RT-PCR).
Further, we have examined expression of these enzymes in
primary epithelial and stromal cultures derived from human breast
tumours to determine their cellular localization. Finally, as the
cytokine IL-6 appears to have a key role in the regulation of
aromatase, 17-HSD type STS complexes and I (Adams et al, 1991;
Speirs et al, 1993; Purohit et al, 1997) we investigated whether
expression of IL-6 was associated with a specific enzyme profile.
METHODS
Tumour samples
Breast tumours were obtained from 51 patients who presented
sequentially for surgical removal of a clinically confirmed breast
lesion. Tumours were identified and clinically staged using the
Nottingham grading system by a consultant pathologist, details of
which are presented in Table 1. Surgical samples were immedi-
ately snap-frozen and stored at –80°C until analysed. Ethical
approval was obtained and all patients gave informed consent.
RNA extraction and cDNA synthesis
Frozen breast tissue was pulverized using a mortar and pestle and
total RNA extracted with Trizol (Life Technologies, Paisley, UK)
according to the manufacturer’s instructions. One microgram of
RNA was used as a template for first strand synthesis as pre-
viously described (Green et al, 1997).
Qualitative PCR amplification
Primers were obtained from Life Technologies and were designed
from published gene sequences. Sequences, product sizes and
restriction mapping details for all primer pairs are illustrated in
Table 2. Details on primers used for amplification of the IL-6 gene
have previously been published (Green et al, 1997). To check
cDNA integrity, fragments of glyceraldehyde phosphate dehydro-
genase (GAPDH), a standard housekeeping gene, were amplified
in parallel (data not shown). The PCR reaction contained: 2 units
of BIOTAQ, 10 ´ PCR buffer (containing 1.5 mM magnesium
Table 1 Clinicopathological details of the tumours under study
Parameter Number
Patients
Total number in study 51
Age (years)
Mean 62
Range 35–88
Tumour histology
Ductal 45
Lobular 4
Othera 2
Grade
I2
II 23
III 18
Unknown 7
Node status
+2 2
–2 3
Unknown 6
Menopausal status
Pre 9
Post 42
aThis group comprised one apocrine and one carcinoma of mixed
lobular/ductal pathology
Table 2 Primer sequences, expected product sizes and restriction mapping details
Primer sequence Product size (bp) Restriction enzyme Cleaved products (bp)
17-HSD I
5¢-GTGGACGTGCTGGTGTGTAA-3¢
5¢-TGGAAGGTGTGGATGTCCGT-3¢ 389 Hinf I 252, 187
17-HSD II
5¢-CTGAGGAATTGCGAAGAACC-3¢
5¢-GAAGTCCTTGCTGGCTAACG-3¢ 593 Pst I 484, 109
17-HSD III
5¢-ACAATGTCGGAATGCTTCCA-3¢
5¢-AGGTTGAAGTGCTGGTCTGC-3¢ 624 Dde I 238, 205, 181
17-HSD IV
5¢-TCTATGATGGGTGGAGGATT-3¢
5¢-GCGGCGTCCTATTTCCTCAA-3¢ 750 EcoR I 595, 155
Aromatase
5¢-GCCCCCTCTGAGGTCAAGGAACACA-3¢
5¢-CACCCGGTTGTAGTAGTTGCAGGCACT-3¢ 267 Hinf I 217, 50
Steroid sulphatase
5¢-TCCTACTGTTCTTTCTGTGG-3¢
5¢-CTTGCAGTCTCTCAGATTGGT-3¢ 482 Ava II 255, 227692 V Speirs et al
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chloride; both Bioline, London, UK), 0.5 mg of each oligo-
nucleotide primer, 200 mM each of dATP, dCTP, dGTP and dTTP,
1 ml nascent cDNA and sterile distilled water to bring the volume
to 50 ml. The following were used as positive controls: for 17-HSD
I, II, IV and STS cDNA from the human breast cancer cell line
BT-20; for 17-HSD III, human testes cDNA; for aromatase human
fibroblast cDNA; for IL-6 human meningioma cDNA (Boyle-
Walsh et al, 1996). Negative controls included substitution of
RNA or cDNA with distilled water, or substitution of cDNA with
an irrelevant cDNA (synthesized from human tibialis anterior
muscle). All transcripts were analysed in parallel on at least two
separate occasions in a thermal cycler (Hybaid OmniGene,
Teddington, UK) with the following cycle: a denaturation step at
94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 57.5°C for
30 s, 72°C for 30 s and a final primer extension step of 72°C for
5 min. PCR products were analysed by electrophoresis through a
1.2% agarose gel and visualized by ethidium bromide staining
under UV illumination.
Restriction enzyme digests
Restriction digests were performed on representative PCR pro-
ducts to confirm the identity of the PCR products. Five microlitres
of amplified product was digested with the appropriate restriction
enzyme (see Table 2) for 2 h at 37°C. Digested products were then
electrophoresed through a 2% agarose gel and visualized as above.
Primary cultures
Epithelial or stromal-enriched cultures were prepared from
22 breast tumours. Tumours were digested overnight in 0.1%
collagenase III (Life Technologies; Speirs et al, 1996a). The tissue
digest was separated into epithelial or stromal fractions by differ-
ential centrifugation followed by culture in selective medium as
previously described (Speirs et al, 1996b, 1998a). Cell were lysed
in situ by the addition of Trizol directly to the culture dishes and
the resulting RNA reverse transcribed into cDNA, which was
amplified by PCR as outlined above.
Statistical analysis
Differences were calculated using Fisher’s Exact test.
RESULTS
Expression of genes for steroid converting enzyme in
breast tumours
Combinations of steroid-converting enzymes expressed by breast
tumours were analysed and compared. The results are presented in
Table 3. All except a single tumour expressed at least one isoform
of 17-HSD either alone or in combination with aromatase or STS.
Nine tumours expressed all four isoforms of 17-HSD, with 3/9
additionally expressing STS and a further 3/9 co-expressing STS
and aromatase. Fifteen tumours expressed three 17-HSD isoforms.
Of those which exclusively expressed 17-HSD, a combination of
17-HSD II, III and IV was most common, observed in 6/15
samples. Where 17-HSD was expressed in combination with
aromatase and STS, combinations of 17-HSD II, III and IV were
most common (6/15 samples). The majority of tumours expressed
two isoforms of 17-HSD with combinations of 17-HSD II and IV
predominant. Eight samples expressed a single isoform of which
17-HSD I, expressed by 5/8 samples was most common. Only one
tumour failed to express either one of the 17-HSD isoforms,
aromatase or STS and one sample expressed aromatase only.
Representative PCR products and restriction-mapped products to
confirm identity are illustrated in Figure 1.
Table 3 Co-expression of 17b-hydroxysteroid dehydrogenase (17-HSD)
isoforms alone or in combination with aromatase (ARO) and steroid
sulphatase (STS) in human breast tumours
HSD isoform HSD only HSD HSD HSD
+ARO +STS +ARO +STS
4 isoforms (n = 9) 3 0 3 3
3 isoforms (n = 15)
I, II and III 1 1 2 0
I, II and IV 3 0 0 0
I, II and IV 0 1 0 1
II, III and IV 1 1 1 3
2 isoforms (n = 17)
I and II 1 1 1 0
I and III 1 0 0 0
I and IV 1 0 0 0
II and III 0 0 1 0
II and IV 1 0 5 1
III and IV 1 0 1 2
1 isoform (n = 8)
I5 0 0 0
II 1 0 0 0
III 0 0 0 0
IV 1 0 1 0
No isoforms (n = 2) 1 1 0 0
La b c d e f L
Figure 1 Representative agarose gel showing original PCR product
(left lane) and the fragments resulting from restriction endonuclease
digestion (right lane). L = 100 bp marker (Life Technologies), a = 17-HSD I
(389), b = 17-HSD-II (593), c = 17-HSD III (624), d = 17-HSD IV (750),
e = aromatase (267), f = STS (482). Numbers in parentheses refer to the
expected size (bp) of PCR product. Arrowhead = 600 bp
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Figure 2 Relative expression of 17-HSD I-IV, aromatase and STS genes in
cultures of epithelial and stromal cells derived from breast tumours. Data is
as a percentage (samples which expressed the gene divided by the total
number under study)Steroid-converting enzymes in breast 693
British Journal of Cancer (1999) 81(4), 690–695 © 1999 Cancer Research Campaign
Expression of genes for steroid-converting enzyme in
breast primary cultures
To determine if expression of specific genes was associated with a
specific cell type, paired epithelial or stromal primary cultures
were established from 22 breast tumours. The phenotypic identity
of these cultures (all used at passage 1) has previously been
characterized by immunostaining, flow cytometry and gene
expression studies (Speirs et al, 1996b, 1998). Data are illustrated
in Figure 2. In epithelial cultures, expression was ranked: HSD I
(86%) > STS (77%) > HSD II (59%) > HSD IV (50%) =
aromatase (50%) > HSD III (32%). With the exception of
aromatase, expression in stromal cultures was generally reduced
and was ranked: HSD I (68%) > STS (67%) > aromatase (48%) >
HSD II (43%) > HSD IV (28%) > HSD III (19%).
Correlation between 17-HSD isoforms, aromatase and
STS and IL-6 gene expression
Samples, which expressed combinations of 17-HSD isoforms,
aromatase and STS with IL-6, were analysed and compared. As
illustrated in Table 4, samples which expressed three or more
steroid-converting enzymes also tended to express IL-6. These
samples tended to be of a higher grade and, additionally had a
family history of breast cancer. No further relationships were
observed between enzyme profiles and other clinical features
including tumour type, stage or grade node or steroid receptor
status (data not shown).
DISCUSSION
Clinical, epidemiological and laboratory data indicate that oestro-
gens are the most important mitogenic stimulants in breast cancer
and local production of oestrogen is of significance in the progres-
sion of this disease. Three main steroid-converting enzyme
complexes, namely, aromatase, 17-HSD and STS, govern in situ
production of oestrogen. In this study we have investigated the
presence and distribution of these enzyme complexes in human
breast cancer and their association with the cytokine IL-6, which is
emerging as having a key role in regulating oestrogen synthesis in
breast cancer.
Patterns of enzyme expression were highly variable between
individual tumours. However, the majority of samples expressed
either two (n = 17) or three (n = 15), isoforms of 17-HSD, either
alone or in combination with aromatase or STS. Since 17-HSD
type I is the principal enzyme in breast tissue, catalysing the reduc-
tion of the weaker oestrogen, oestrone (E1) into E2 (Peltoketo
et al, 1996), one might predict that this isoform would be present
in most of these samples. However, this was not the case. In
tumours expressing three isoforms, combinations of 17-HSD types
II, III and IV were most common, found in 40% of samples.
Similarly, in samples expressing two isoforms, combinations of
17-HSD types II and IV predominated (41% of samples). To
explain these findings, the specific functions of the steroid-
converting enzymes under study should be considered. 17-HSD
type II oxidizes testosterone and E2 into androstendione and E1
(Luu-The et al, 1995; Penning, 1996). The function of 17-HSD
type IV is similar in that it oxidizes oestrogens and androgens
(Adamski et al, 1992). Much of the E1 formed from androsten-
dione is converted by STS to oestrone sulphate, which acts as a
reservoir for the formation of E1 via STS (Reed et al, 1994). One
could speculate that to produce the biologically more potent E2
associated with breast tumours, the aromatase and STS complexes
then take over by converting testosterone or oestrone sulphates
into E2. In those tumours lacking 17-HSD type I, this would
circumvent the need for this isoform. A schematic representation
showing the proposed relationship between 17-HSD types II and
IV, aromatase and STS is illustrated in Figure 3.
An unexpected observation was the presence of transcripts for
17-HSD type III in breast tissue. This isoform is found principally
in tests where it reduces androstendione to testosterone
(Andersson, 1995). Unlike the isoforms for type I, II and IV, which
have been detected in a variety of tissue types (Penning, 1996),
other groups have failed to detect the 17-HSD type III gene in
either ovary (Zhang et al, 1996), or prostate (Elo et al, 1996;
Castagnetta et al, 1997). However, it has recently been detected in
human adipose tissue (Corbould et al, 1998). Given that human
breast tissue contains adipocytes, one might predict that its
expression may be associated with these cells. However, we also
observed the gene in breast primary cultures. These cultures have
been fully characterized using a number of cellular and genetic
markers and under the culture conditions described are unlikely to
Table 4 Associations in expression of 17b-hydroxysteroid dehydrogenase
(17-HSD) isoforms, aromatase (ARO) and steroid sulphatase (STS) with IL-6
in human breast tumours
HSD isoform HSD only HSD HSD HSD
+ARO +STS +ARO+STS
Interleukin-6
+– +– + –+ –
4 isoforms (n = 9) 2a 1 002 13 0
3 isoforms (n = 15) 3 2 2 0 3 0 4 1
2 isoforms (n = 15) 2 3 0 1 3 5 1 0
1 isoforms (n = 8) 3 4 0 0 1 0 0 0
No isoforms (n = 2) 1 0 0 1 0 0 0 0
aEach entry represents the number of samples expressing a particular gene
combination.
17-HSD type II
4-androstenedione Testosterone
Aromatase
STS
Aromatase
STS
E1-sulphate
17-HSD types II, IV
E1 E2
E2-sulphate
Figure 3 Schematic representation of the relationship between 17-HSD
types II and IV, aromatase and STS. Enzyme pathways are represented
in italics. Arrows refer to preferred direction of enzyme.
E1 = 17b-oestradiol, E2 = oestrone, STS = steroid sulphatase694 V Speirs et al
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contain adipocytes (Speirs et al, 1996b, 1998a). Furthermore, the
observation of 17-HSD type III expression in human pituitary
adenomas (Green et al, 1999) and in a human colonic carcinoma
cell line (English et al, 1997) lends further support for an active
role of 17-HSD type III in steroid metabolism.
Like all studies which evaluate gene expression, PCR gives no
indication of whether the gene transcripts go on to be translated
and transcribed into bioactive enzyme in breast tumours.
Nevertheless there is good evidence that these enzyme complexes
are active in tumours and isolated cell types. We have recently
reported a correlation between gene expression and enzyme
activity for 17-HSD type I in epithelial and stromal cells cultured
derived from breast tumours (Speirs et al, 1998b) and pituitary
adenomas (Green et al, 1999). Similar correlations have been
observed for STS and aromatase (Lu et al, 1996; Pasqualini et al,
1996b; Sasano et al, 1996). In a previous study, we have confirmed
by ELISA that the IL-6 gene is translated and secreted as a bio-
active peptide in breast primary cultures (Green et al, 1997).
In general, our in vitro data showed that genes for steroid-
converting enzymes were more likely to be expressed by epithelial
cells compared with stromal cells. Of the six genes analysed,
17-HSD I and STS were observed in a greater number of samples
(in epithelial cultures, 86% and 77% respectively). Although it is
possible that removing a cell from its internal microenvironment
and placing it under in vitro conditions may alter its phenotypic
characteristics, our data correlates with previous studies looking at
enzyme activity. These studies showed that 17-HSD I (Speirs et al,
1998) and STS (James et al, 1987) had highest levels of activity in
breast tumours. Further, with aromatase we observed the gene in
approximately 50% of samples, complementing an earlier study on
aromatase activity in breast tumours (Tilson-Mallet et al, 1983).
Immunostaining data reveals that the aromatase enzyme is located
in both epithelial and stromal cells (Santen et al, 1994; Lu et al,
1996; Sasano et al, 1996).
Cytokines have emerged as key regulators of E2 synthesis in
the breast, in particular IL-6. As IL-6 can stimulate the activity of
17-HSD, aromatase and STS (Adams et al, 1991; Speirs et al,
1993; Purohit et al, 1997), we investigated whether there was a
relationship between expression of IL-6 with 17-HSD isoforms,
aromatase and STS. In general, samples which expressed at least
three isoforms of 17-HSD in combination with IL-6 tended to be
of higher grade (either grades II or III). Those which expressed all
six enzymes in combination with IL-6 were of grade III. Further
analysis revealed that tumours which expressed IL-6 and enzyme
combinations which included HSD I, aromatase and STS came
from patients with grade III carcinomas and from those with a
family history of breast cancer (first-degree relative). These
enzymes are regarded as being most critical in regulating
oestrogen concentrations in breast cancer, and furthermore their
activities are significantly up-regulated by IL-6 in vitro (Purohit
et al, 1997). Our observation that these factors are associated with
more aggressive tumours could indicate that co-expression of IL-6
with HSD type I, aromatase and STS may be useful as independent
prognostic factors in breast cancer.
It is worth noting that paradoxically, whilst IL-6 stimulates
oestrogen production via these enzyme complexes, oestrogen itself
can down-regulate IL-6 at the transcriptional level (Ray et al,
1994; Kurebayashi et al, 1997). These inhibitory effects appear to
be indirect, interfering with the function of the transcription factor
NF-kB (Kurebayashi et al, 1997). Furthermore, as aberrant
expression of NF-kB has been observed in many breast tumours
(Sovak et al, 1997), the inhibitory effects of oestrogens on IL-6
transcription may be lost.
In conclusion, we have shown that breast tumours show 
considerable heterogeneity in expression of steroid-converting
enzymes. We propose that these enzymes work in tandem, prob-
ably in association with cytokines, thereby providing sufficient
quantities of bioactive oestrogen from less active precursors which
stimulates tumour growth. Detection of these enzymes in cultures
enriched for stromal as well as epithelial cells could indicate
modulation of enzyme activity by the stroma. This may represent a
novel paracrine mechanism which increases availability of E2 to
breast tumours.
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